Fig. 1 | British Journal of Cancer

Fig. 1

From: A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

Fig. 1

Pharmacodynamic response in tumour samples evaluated at baseline (pre-dose) and kpost-dosing of GSK2256098 and trametinib for 22 days. The expression level relative to baseline levels (normalized to 100%; Dark grey bars) of pFAK and pERK normalised to the level of FAK in the sample. The ratio of the pFAK level relative to FAK and the pERK level relative to FAK are shown for each subject and are indicative of kinase inhibition by GSK2256098 and trametinib, respectively (Light grey bars). a) Subject #200 dosed with GSK2256098 at 500 mg BID and trametinib at 0.5 mg QD. b Subject #202 dosed with GSK2256098 at 250 mg BID and trametinib at 0.5 mg QD

Back to article page